

23-06-2020

PRESS RELEASE  
Regulated information



## Information on the Total Number of Voting Rights (Denominator)

Liege, Belgium, 23 June 2020 – 17:45 CEST – In accordance with article 15 of the Belgian Act of 2 May 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions, Mithra Pharmaceuticals SA (the "Company" or "Mithra") announces the following information, following the issuance of 3,421,052 new shares on 23 June 2020 for an amount of EUR 65.0 million in gross proceeds in the framework of the private placement via an accelerated bookbuild offering publicly announced on 18 June 2020.

Following this capital increase, Mithra now has 42,554,297 outstanding shares carrying voting rights (39,133,245 outstanding shares carrying voting rights previously).

Therefore, Mithra publishes the following updated information:

- Share capital: EUR 31,153,882.82
- Total number of securities carrying voting rights: 42,554,297 (all ordinary shares)
- Total number of voting rights (= denominator): 42,554,297 (all relating to ordinary shares)
- Number of outstanding rights to subscribe to securities carrying voting rights:
  - Pursuant to the share option plan of 2 March 2015: 620 subscription rights giving right to 1,023,000 ordinary shares
  - Pursuant to the share option plan of 5 November 2018: 1,785,617 subscription rights giving right to 1,785,617 ordinary shares

\*\*\*\*\*

### For more information, please contact:

**Alexandra Deschner (IRO)** : +32 490 58 35 23 - [investorrelations@mithra.com](mailto:investorrelations@mithra.com)

**Maud Vanderthommen (Press)** : +32 473 58 61 04 – [press@mithra.com](mailto:press@mithra.com)

### About Mithra

*Mithra (Euronext: MITRA) is a Belgian biotech company dedicated to transforming Women's Health by offering new choices through innovation, with a particular focus on contraception and menopause. Mithra's goal is to develop products offering better efficacy, safety and convenience, meeting women's needs throughout their life span. Its three lead development candidates are built on Mithra's unique native estrogen platform, Estetrol (E4): Estelle®, a new era in oral contraception, PeriNesta®, the first complete oral treatment targeting perimenopause and Donesta®, the next-generation hormone therapy. Mithra also develops and manufactures complex therapeutics in the areas of contraception, menopause and hormone-dependent cancers. It offers partners a complete spectrum of research, development and specialist manufacturing at its technological platform Mithra*

23-06-2020

PRESS RELEASE  
Regulated information

CDMO. Active in more than 100 countries around the world, Mithra has an approximate headcount of 250 staff members and is headquartered in Liège, Belgium. [www.mithra.com](http://www.mithra.com)

### Important information

*This announcement is not for distribution, directly or indirectly, in or into the United States. It does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), and the securities may not be offered or sold in the United States (as defined in Regulation S under the U.S. Securities Act) unless these securities are registered under the U.S. Securities Act, or an exemption from the registration requirements of the U.S. Securities Act is available. The Company and its affiliates have not registered, and do not intend to register, any portion of the offering of the securities concerned in the United States, and do not intend to conduct a public offering of securities in the United States.*

---



News  
Alerts

Subscribe to our mailing list on [investors.mithra.com](http://investors.mithra.com) to receive our press releases by email or follow us on our social media :

[Linkedin](#) • [Twitter](#) • [Facebook](#)